Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 11, 2012, Pages 2803-2812

  Tang, W H Wilson ^a   Hartiala, Jaana ^b   Fan, Yiying ^c   Wu, Yuping ^c   Stewart, Alexandre F R ^d   Erdmann, Jeanette ^e   Kathiresan, Sekar ^f   Roberts, Robert ^d   McPherson, Ruth ^d   Allayee, Hooman ^b   Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CLEVELAND STATE UNIVERSITY   (United States)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^e UNIVERSITY OF LÜBECK   (Germany)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Arylesterase activity; Coronary artery disease; Oxidative stress; Paraoxonase 1 gene

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; BIOLOGICAL MARKER; CARBOXYLESTERASE; PON1 PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DISEASE CLASSIFICATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HIGH THROUGHPUT SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CEREBROVASCULAR ACCIDENT; CHI SQUARE DISTRIBUTION; DOWN REGULATION; ENZYMOLOGY; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED STATES;

AGED; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; OHIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS;

EID: 84871876039     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.253930     Document Type: Article

References (16)

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325.
2. Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact. 1999;119-120:429-438.
3. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
4. Shih DM, Lusis AJ. The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol. 2009;20:288-292.
5. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473-480.
6. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/aryles-terase. Anal Biochem. 1989;180:242-247.
7. Tang WH, Wu Y, Mann S, Pepoy M, Shrestha K, Borowski AG, Hazen SL. Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure. Circ Heart Fail. 2011;4:59-64.
8. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265-1276.
9. Willer CJ, Sanna S, Jackson AU, et al. Newly identifed loci that infu-ence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161-169.
10. Preuss M, König IR, Thompson JR, et al; CARDIoGRAM Consortium. Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet. 2010;3:475-483.
11. Deakin S, Guernier S, James RW. Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin. Pharmacogenet Genomics. 2007;17:451-457.
12. Ferretti G, Bacchetti T, Masciangelo S, Bicchiega V. HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity (Silver Spring). 2010;18:1079-1084.
13. Himbergen TM, van Tits LJ, Voorbij HA, de Graaf J, Stalenhoef AF, Roest M. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modifed by paraoxonase-1 in patients with familial hypercholesterolaemia. J Intern Med. 2005;258:442-449.
14. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693-2708.
15. She ZG, Zheng W, Wei YS, Chen HZ, Wang AB, Li HL, Liu G, Zhang R, Liu JJ, Stallcup WB, Zhou Z, Liu DP, Liang CC. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice. Circ Res. 2009;104:1160-1168.
16. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106:484-490.